Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Reveglucosidase alfa - BioMarin Pharmaceutical

Drug Profile

Reveglucosidase alfa - BioMarin Pharmaceutical

Alternative Names: BMN-701; GILT-recombinant-human-acid-alfa-glucosidase; GILT-rhGAA; GILT-rhGAA - BioMarin Pharmaceutical; GILT-tagged recombinant human GAA; Glycosylation-independent-lysosomal-targeting-rhGAA; IGF2-GAA; Insulin-like-growth-factor-2-GAA; ZC-701

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZyStor Therapeutics
  • Developer BioMarin Pharmaceutical
  • Class Alpha-glucosidases; Recombinant fusion proteins
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glycogen storage disease type II

Most Recent Events

  • 23 May 2018 BioMarin terminates a phase II trial in Glycogen storage disease type II in USA, United Kingdom, Australia, Germany, France and New Zealand as the company decided to end the overall development program based on competing corporate priorities (IV) (NCT01435772)
  • 30 Jun 2016 Discontinued - Phase-I/II for Glycogen storage disease type II in France (IV)
  • 30 Jun 2016 Discontinued - Phase-II for Glycogen storage disease type II in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top